GlaxoSmithKline has £1.6bn offer rejected

Drugs giant GlaxoSmithKline said it was disappointed that an offer worth £1.6bn (€1.94bn) for US-based Human Genome Sciences (HGS) has been rejected.

GlaxoSmithKline has £1.6bn offer rejected

Drugs giant GlaxoSmithKline said it was disappointed that an offer worth £1.6bn (€1.94bn) for US-based Human Genome Sciences (HGS) has been rejected.

Despite an 81% premium to its Wednesday share price, HGS said the move undervalued its business.

You have reached your article limit. Already a subscriber? Sign in

Continue reading for €5

Unlock unlimited access and exclusive benefits

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited